Here, using both in vitro and in vivo model systems including human prostate orthograft and genetically modified (Gao et al, 2012) pre‐clinical murine models, we uncovered a functional role of SPRY2 deficiency in the progression of prostate cancer to CRPC state through bidirectional tumour–host interactions. Here, SPRY2 is linked to prostate cancer.